Compare COOK & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | WHWK |
|---|---|---|
| Founded | 1985 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 170.4M | 187.4M |
| IPO Year | 2021 | 2017 |
| Metric | COOK | WHWK |
|---|---|---|
| Price | $63.49 | $4.77 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $53.00 | $7.50 |
| AVG Volume (30 Days) | 66.8K | ★ 443.3K |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 86.02 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $559,520,000.00 | $7,145,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.07 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.48 | $1.57 |
| 52 Week High | $86.59 | $5.50 |
| Indicator | COOK | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 64.22 |
| Support Level | $58.44 | $3.79 |
| Resistance Level | $76.22 | $4.82 |
| Average True Range (ATR) | 4.99 | 0.29 |
| MACD | -0.14 | 0.11 |
| Stochastic Oscillator | 59.66 | 83.89 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.